Screener
Agios Pharmaceuticals AGIO Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Operating lease liabilities | 19,225 | 18,392 |
| Total current liabilities | 70,217 | 82,206 |
| Operating lease liabilities, net of current portion | 11,946 | 21,815 |
| Other non-current liabilities | 240 | 90 |
| Total liabilities | 82,403 | 104,111 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 75,821,241 shares issued and 59,604,830 outstanding at June 30, 2026, and 74,665,003 shares issued and 58,448,592 outstanding at December 31, 2025 | 76 | 75 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's other non-current liabilities?
- Agios Pharmaceuticals (AGIO) reported other non-current liabilities of $240K in Q2 2026.
- How has Agios Pharmaceuticals's other non-current liabilities changed year-over-year?
- Agios Pharmaceuticals's other non-current liabilities increased by 137.6% year-over-year, from $101K to $240K.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Agios Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude